Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report)’s stock price traded up 3.2% on Tuesday . The company traded as high as $6.6036 and last traded at $6.6036. 173 shares changed hands during trading, a decline of 93% from the average session volume of 2,602 shares. The stock had previously closed at $6.40.
Clinuvel Pharmaceuticals Trading Up 3.2%
The stock’s 50-day simple moving average is $6.71 and its two-hundred day simple moving average is $7.47.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
